TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Stock
Certificat
DE000CJ5PZU8
| Market Closed - Börse Stuttgart 02:24:51 2024-05-17 EDT | ||
| 21.43 EUR | +0.14% |
|
| Current month | +3.78% | ||
| 1 month | +6.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 21.43 | +0.14% |
| 24-05-16 | 21.4 | -0.37% |
| 24-05-15 | 21.48 | +0.42% |
| 24-05-14 | 21.39 | +2.79% |
| 24-05-13 | 20.81 | +0.14% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 02:24 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | CJ5PZU |
| ISIN | DE000CJ5PZU8 |
| Date issued | 2018-11-06 |
| Strike | 116.1 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.97 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.63 € |
|---|---|
| Lowest since issue | 0.9 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- Certificat
